Cancer Research SABCS Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 67, 7082, August 1, 2007. doi: 10.1158/0008-5472.CAN-07-1872
© 2007 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Metz, R.
Right arrow Articles by Prendergast, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metz, R.
Right arrow Articles by Prendergast, G. C.

Priority Reports

Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound D-1-Methyl-Tryptophan

Richard Metz1, James B. DuHadaway1, Uma Kamasani1, Lisa Laury-Kleintop1, Alexander J. Muller1,2 and George C. Prendergast1,2

1 Lankenau Institute for Medical Research, Wynnewood, Pennsylvania and 2 Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania

Requests for reprints: George C. Prendergast, Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096. Phone: 610-645-8475; Fax: 610-645-8533; E-mail: prendergast{at}limr.org.

Small-molecule inhibitors of indoleamine 2,3-dioxygenase (IDO) are currently being translated to clinic for evaluation as cancer therapeutics. One issue related to trials of the clinical lead inhibitor, D-1-methyl-tryptophan (D-1MT), concerns the extent of its biochemical specificity for IDO. Here, we report the discovery of a novel IDO-related tryptophan catabolic enzyme termed IDO2 that is preferentially inhibited by D-1MT. IDO2 is not as widely expressed as IDO but like its relative is also expressed in antigen-presenting dendritic cells where tryptophan catabolism drives immune tolerance. We identified two common genetic polymorphisms in the human gene encoding IDO2 that ablate its enzymatic activity. Like IDO, IDO2 catabolizes tryptophan, triggers phosphorylation of the translation initiation factor eIF2{alpha}, and (reported here for the first time) mobilizes translation of LIP, an inhibitory isoform of the immune regulatory transcription factor NF-IL6. Tryptophan restoration switches off this signaling pathway when activated by IDO, but not IDO2, arguing that IDO2 has a distinct signaling role. Our findings have implications for understanding the evolution of tumoral immune tolerance and for interpreting preclinical and clinical responses to D-1MT or other IDO inhibitors being developed to treat cancer, chronic infection, and other diseases. [Cancer Res 2007;67(15):7082–7]




This article has been cited by other articles:


Home page
 J. Immunol.Home page
N. A. Barnes, S. J. Stephenson, R. M. Tooze, and G. M. Doody
Amino Acid Deprivation Links BLIMP-1 to the Immunomodulatory Enzyme Indoleamine 2,3-Dioxygenase
J. Immunol., November 1, 2009; 183(9): 5768 - 5777.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Baban, P. R. Chandler, M. D. Sharma, J. Pihkala, P. A. Koni, D. H. Munn, and A. L. Mellor
IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells
J. Immunol., August 15, 2009; 183(4): 2475 - 2483.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. J. Chung, M. Rossi, E. Romano, J. Ghith, J. Yuan, D. H. Munn, and J. W. Young
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells
Blood, July 16, 2009; 114(3): 555 - 563.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Qian, J. Villella, P. K. Wallace, P. Mhawech-Fauceglia, J. D. Tario Jr., C. Andrews, J. Matsuzaki, D. Valmori, M. Ayyoub, P. J. Frederick, et al.
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
Cancer Res., July 1, 2009; 69(13): 5498 - 5504.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. N. Scott, J. DuHadaway, E. Pigott, N. Ridge, G. C. Prendergast, A. J. Muller, and L. Mandik-Nayak
The Immunoregulatory Enzyme IDO Paradoxically Drives B Cell-Mediated Autoimmunity
J. Immunol., June 15, 2009; 182(12): 7509 - 7517.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Boasso, M. Vaccari, D. Fuchs, A. W. Hardy, W.-P. Tsai, E. Tryniszewska, G. M. Shearer, and G. Franchini
Combined Effect of Antiretroviral Therapy and Blockade of IDO in SIV-Infected Rhesus Macaques
J. Immunol., April 1, 2009; 182(7): 4313 - 4320.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al.
Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase
Cancer Res., April 1, 2009; 69(7): 3228 - 3237.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Blood, March 12, 2009; 113(11): 2394 - 2401.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. C. O'Connor, M. A. Lawson, C. Andre, E. M. Briley, S. S. Szegedi, J. Lestage, N. Castanon, M. Herkenham, R. Dantzer, and K. W. Kelley
Induction of IDO by Bacille Calmette-Guerin Is Responsible for Development of Murine Depressive-Like Behavior
J. Immunol., March 1, 2009; 182(5): 3202 - 3212.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M.-C. Yen, C.-C. Lin, Y.-L. Chen, S.-S. Huang, H.-J. Yang, C.-P. Chang, H.-Y. Lei, and M.-D. Lai
A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA
Clin. Cancer Res., January 15, 2009; 15(2): 641 - 649.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M. Gasparri, E. Jachetti, B. Colombo, A. Sacchi, F. Curnis, G.-P. Rizzardi, C. Traversari, M. Bellone, and A. Corti
Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFN{gamma}
Mol. Cancer Ther., December 1, 2008; 7(12): 3859 - 3866.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. J. Muller, M. D. Sharma, P. R. Chandler, J. B. DuHadaway, M. E. Everhart, B. A. Johnson III, D. J. Kahler, J. Pihkala, A. P. Soler, D. H. Munn, et al.
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase
PNAS, November 4, 2008; 105(44): 17073 - 17078.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
L. Harrington, C. V. Srikanth, R. Antony, S. J. Rhee, A. L. Mellor, H. N. Shi, and B. J. Cherayil
Deficiency of Indoleamine 2,3-Dioxygenase Enhances Commensal-Induced Antibody Responses and Protects against Citrobacter rodentium-Induced Colitis
Infect. Immun., July 1, 2008; 76(7): 3045 - 3053.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Lob, A. Konigsrainer, R. Schafer, H.-G. Rammensee, G. Opelz, and P. Terness
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Blood, February 15, 2008; 111(4): 2152 - 2154.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.